Brainstorm Cell Therapeutics (BCLI) Misses Q2 EPS by 19c
Tweet
Share
E-mailGet Alerts BCLI Hot Sheet
Join SI Premium – FREE
Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q2 EPS of ($0.34), $0.19 worse than the analyst estimate of ($0.15).
For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
- Morgan Stanley upgrades CDW on stronger AI-driven server demand
- Worthington Enterprises raises dividend 5%, adds board member
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
